Mark J. Tarr, President & CEO of Encompass Health Corporation (EHC), has demonstrated a clear selling bias in his recent insider transactions, with $28 million in total sales outweighing $7.1 million in purchases across 26 reported trades. His activity has been exclusively concentrated in EHC shares, with no transactions in other companies. The most significant disposals occurred on February 11, 2026, when Tarr executed six separate sales totaling $17.1 million, including a single $9.9 million transaction—his largest reported trade. This selling pattern has continued through early March 2026, with a $3.8 million sale on March 2 following smaller February dispositions totaling $5.3 million, including a $4.6 million transaction on February 19.
Tarr's buying activity appears more sporadic, with his last open-market purchase occurring on March 4, 2025, for $3.3 million. The majority of his acquisitions fall under code "A" (award or grant), while his sales are predominantly coded "S" (open market sale) or "F" (tax withholding). Smaller, recurring transactions—often in the $200,000 range—appear related to tax obligations, as they frequently occur in late February across multiple years. The absence of recent purchases alongside sustained selling, particularly the cluster of high-value disposals in early 2026, suggests a deliberate reduction in his EHC position over time.
AI-assisted summary